

### Contents

	Foreword
1	Scope
2	Normative references
3	Terms and definitions
4	Summary of good clinical practice (GCP) principles
5	Ethical considerations
5.1	General
5.2	Improper influence or inducement
5.3	Compensation and additional health care
5.4	Registration in publicly accessible database
5.5	Responsibilities
5.6	Communication with the ethics committee (EC)
5.6.1	General
5.6.2	Initial EC submission
5.6.3	Information to be obtained from the EC
5.6.4	Continuing communication with the EC
5.6.5	Continuing information to be obtained from the EC
5.7	Vulnerable populations
5.8	Informed consent
5.8.1	General
5.8.2	Process of obtaining informed consent
5.8.3	Special circumstances for informed consent
5.8.3.1	General
5.8.3.2	Subject needing legally designated representatives
5.8.3.3	Subject unable to read or write
5.8.3.4	Emergency treatments
5.8.4	Information to be provided to the subject
5.8.5	Informed consent signature
5.8.6	New information
6	Clinical investigation planning
6.1	General
6.2	Risk management
6.2.1	General
6.2.2	Investigational device including clinical procedure risks and their disclosure
6.2.3	Clinical investigation process
6.3	Justification for the design of the clinical investigation
6.4	Clinical investigation plan (CIP)
6.5	Investigator's brochure (IB)
6.6	Case report forms (CRFs)
6.7	Monitoring plan
6.8	Investigation site selection
6.9	Agreement(s)
6.10	Labelling
6.11	Data monitoring committee (DMC)
7	Clinical investigation conduct
7.1	General

- 7.2 Investigation site initiation
  - 7.3 Investigation site monitoring
  - 7.4 Adverse events and device deficiencies
    - 7.4.1 Signals requiring immediate action
    - 7.4.2 Adverse events
    - 7.4.3 Device deficiencies
    - 7.4.4 Risk assessment process for potentially unacceptable risks
  - 7.5 Clinical investigation documents and documentation
    - 7.5.1 Amendments
    - 7.5.2 Subject identification log
    - 7.5.3 Source documents
  - 7.6 Additional members of the investigation site team
  - 7.7 Subject privacy and confidentiality of data
  - 7.8 Document and data control
    - 7.8.1 Traceability of documents and data
    - 7.8.2 Recording of data
    - 7.8.3 Electronic clinical data systems
  - 7.9 Investigational device accountability
  - 7.10 Accounting for subjects
  - 7.11 Auditing
- 8 Suspension, termination, and close-out of the clinical investigation**
- 8.1 Completion of the clinical investigation
  - 8.2 Suspension or premature termination of the clinical investigation
    - 8.2.1 Procedure for suspension or premature termination
    - 8.2.2 Procedure for resuming the clinical investigation after temporary suspension
  - 8.3 Routine close-out
  - 8.4 Clinical investigation report
  - 8.5 Risk assessment and conclusions
  - 8.6 Document retention
- 9 Responsibilities of the sponsor**
- 9.1 Clinical quality management
  - 9.2 Clinical investigation planning and conduct
    - 9.2.1 Selection and training of clinical personnel
    - 9.2.2 Preparation of documents and materials
    - 9.2.3 Conduct of clinical investigation
    - 9.2.4 Monitoring
      - 9.2.4.1 General
      - 9.2.4.2 Qualifications of the monitor
      - 9.2.4.3 Assessment of the investigation site
      - 9.2.4.4 Initiation of the investigation site
      - 9.2.4.5 Routine monitoring visits
      - 9.2.4.6 Close-out activities
      - 9.2.4.7 Monitoring reports
    - 9.2.5 Safety evaluation and reporting
    - 9.2.6 Clinical investigation close-out
  - 9.3 Outsourcing of duties and functions
  - 9.4 Communication with regulatory authorities
- 10 Responsibilities of the principal investigator**
- 10.1 General
  - 10.2 Qualification of the principal investigator
  - 10.3 Qualification of investigation site
  - 10.4 Communication with the EC
  - 10.5 Informed consent process
  - 10.6 Compliance with the CIP
  - 10.7 Medical care of subjects
  - 10.8 Safety reporting
- Annex A (normative) Clinical investigation plan (CIP)**
- A.1 General
    - A.1.1 Introduction
    - A.1.2 Identification of the clinical investigation plan

- A.1.3 Sponsor
- A.1.4 Principal investigator, coordinating investigator and investigation site(s)
- A.1.5 Overall synopsis of the clinical investigation
- A.2 Identification and description of the investigational device
- A.3 Justification for the design of the clinical investigation
- A.4 Benefits and risks of the investigational device, clinical procedure, and clinical investigation
- A.5 Objectives and hypotheses of the clinical investigation
- A.6 Design of the clinical investigation
  - A.6.1 General
  - A.6.2 Investigational device(s) and comparator(s)
  - A.6.3 Subjects
  - A.6.4 Procedures
  - A.6.5 Monitoring plan
- A.7 Statistical design and analysis
- A.8 Data management
- A.9 Amendments to the CIP
  - A.10 Deviations from clinical investigation plan
  - A.11 Device accountability
  - A.12 Statements of compliance
  - A.13 Informed consent process
  - A.14 Adverse events, adverse device effects, and device deficiencies
  - A.15 Vulnerable population (if applicable)
  - A.16 Suspension or premature termination of the clinical investigation
  - A.17 Publication policy
  - A.18 Bibliography

**Annex B (normative) Investigator's brochure (IB)**

- B.1 General
  - B.1.1 Introduction
  - B.1.2 Identification of the IB
  - B.1.3 Sponsor/manufacture
- B.2 Investigational device information
- B.3 Preclinical testing
- B.4 Existing clinical data
- B.5 Risk management of the investigational device
- B.6 Regulatory and other references

**Annex C (informative) Case report forms (CRFs)**

- C.1 General
- C.2 Content and format
  - C.2.1 Overall considerations
  - C.2.2 Cover page/login screen
  - C.2.3 Header or footer/e-CRF identifier
  - C.2.4 Types of CRF
- C.3 Procedural issues

**Annex D (normative) Clinical investigation report**

- D.1 General
- D.2 Cover page
- D.3 Table of contents
- D.4 Summary
- D.5 Introduction
- D.6 Investigational device and methods
  - D.6.1 Investigational device description
  - D.6.2 Clinical investigation plan (CIP)
- D.7 Results
- D.8 Discussion and overall conclusions
- D.9 Abbreviated terms and definitions
- D.10 Ethics
  - D.11 Investigators and administrative structure of clinical investigation
  - D.12 Signature page
  - D.13 Annexes to the report

**Annex E (informative) Essential clinical investigation documents**

**Annex F (informative) Adverse event categorization**

**Annex G (informative) EC responsibilities**

- G.1 General**
- G.2 Responsibilities**
- G.3 Composition, functions, and operations**
- G.4 Information needed**
- G.5 Procedures**
- G.6 EC approval/favourable opinion letters**
- G.7 Records**

**Annex H (informative) Application of ISO 14971 to clinical investigations**

**Annex I (informative) Clinical development stages**

- I.1 Background**
- I.2 Regulatory status**
  - I.2.1 General**
  - I.2.2 Pre-market clinical investigation**
  - I.2.3 Post-market clinical investigation**
- I.3 Clinical development stages**
  - I.3.1 General**
  - I.3.2 Pilot stage**
  - I.3.3 Pivotal stage**
  - I.3.4 Post-market stage**
- I.4 Type of clinical investigation design**
  - I.4.1 General**
  - I.4.2 Exploratory clinical investigation**
  - I.4.3 Confirmatory clinical investigation**
  - I.4.4 Observational clinical investigation**
- I.5 Descriptors of clinical investigations**
  - I.5.1 General**
  - I.5.2 First in human clinical investigation**
  - I.5.3 Early feasibility clinical investigation**
  - I.5.4 Traditional feasibility clinical investigation**
  - I.5.5 Pivotal clinical investigation**
  - I.5.6 Registry**
- I.6 Burden to subjects**
  - I.6.1 General**
  - I.6.2 Interventional clinical investigation**
  - I.6.3 Non-interventional clinical investigation**
- I.7 Applicability of this document's principles**

**Annex J (informative) Clinical investigation audits**

- J.1 General**
- J.2 Sponsor**
- J.3 Investigation site**

**Page count: 83**